Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.
Atevirdine is a nonnucleoside reverse transcriptase inhibitor with in vitro activity against human immunodeficiency virus type 1 and is currently in phase II clinical trials. Atevirdine is most soluble at a pH of < 2, and therefore, normal gastric acidity is most likely necessary for optimal bioavai...
保存先:
| 出版年: | Antimicrob Agents Chemother |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society for Microbiology (ASM)
1996
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC163195/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8851608/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.40.3.767 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|